Trial Profile
Study to elucidate the association of STAT3 expression in tumor cells with the therapeutic outcomes of sunitinib in patients with renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Apr 2018
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 17 Apr 2018 New trial record
- 09 Apr 2018 Results published in the Targeted Oncology